Spun out of Oxford University in 2005, this company specialises in scalable DNA and RNA sequencing technology for biological research, healthcare and industrial applications. The business has developed devices that help scientists identify bacteria and viruses, track disease outbreaks and study the DNA of humans, animals and plants. During the Covid-19 outbreak it has supported public health laboratories around the world using its sequencing devices, and has also developed LamPORE, a low-cost, scalable test for the coronavirus that returns results in one hour. Led by co-founder and chief executive Gordon Sanghera, 59, it sells to more than 100 countries, and revenues hit £52.1m last year. It has secured £529m in venture capital funding — including £48m in May — from investors including Invesco and IP Group.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.